Case Demonstrates Benefit of Integrating CyPath Lung into Standard of Care for Patients Under Surveillance After Treatment for Previous Lung Cancer
bioAffinity Technologies released a case study in which a positive CyPath Lung result led to the detection of a second primary lung cancer in a high-risk patient who was previously diagnosed with stage 1A non-small cell lung cancer and underwent successful surgery in 2023.
“But now we have CyPath Lung. [The patient’s] CyPath result came back as likely cancer, which told me in real time that there were new malignant cells in her lungs.”
“The CyPath Lung test provided real-time information that was pivotal in identifying a second primary lung cancer, which might have been missed with standard follow-up protocols,” bioAffinity Technologies President and CEO Maria Zannes said. “This case underscores the test’s potential to significantly impact patient outcomes by enabling early and accurate detection, especially when imaging reveals small indeterminate nodules that would not immediately lead to invasive diagnostic procedures.”
The patient is a 72-year-old with a 50 pack-year smoking history and significant COPD and chronic respiratory failure who had a wedge resection to remove a non-small cell lung cancer tumor. Postoperative surveillance included regular computed tomography (CT) scans that revealed changes in the scar tissue, raising concerns about potential recurrence.
Health Technology Insights: Viseon Inc. Debuts Hubble AV System in Neurosurgery
“Subtle changes post-op are common and present a diagnostic dilemma. Due to her previous cancer diagnosis, serum markers were contra-indicated, and a PET scan may be inconclusive on smaller nodules,” said Gordon H. Downie, MD, PhD, Director of the Pulmonary Nodule Clinic at Titus Regional Medical Center in Mount Pleasant, Texas. “But now we have CyPath Lung. Her CyPath result came back as likely cancer, which told me in real time that there were new malignant cells in her lungs.”
Prompted by the CyPath score, Dr. Downie ordered a PET scan that revealed significant avidity in the mediastinum and right hilum, along with a new nodule in the right upper lung. A subsequent bronchoscopy confirmed a diagnosis of small cell carcinoma, distinct from the initial NSCLC. This early detection facilitated timely and appropriate treatment for the second primary cancer.
Health Technology Insights: Alpine ENT Expands CareCloud Partnership to Boost Patient Experience
“Each case study illustrates how CyPath® Lung provides actionable information to the physician who can then move forward in the best interest of each patient,” Ms. Zannes said. “By providing earlier and more accurate diagnostic insights, CyPath® Lung improves patient outcomes that can lead to lower healthcare costs for both public and private insurers. We are seeing both clinical and financial benefits with the broader adoption of CyPath® Lung.”
A study published in the Journal of Health Economics Outcomes and Research and authored by pulmonologists Michael Morris, MD, and Sheila Habib, MD, found that an average cost savings of $2,773 per patient would have been achieved in 2022 if CyPath Lung had been part of the standard of care for Medicare patients with a positive lung cancer screening, for a total of $379 million. Adding CyPath® Lung to the standard of care for private-payer patients with a positive lung cancer screening result could have saved even more, an average of $6,460 per patient, an estimated total savings of $895 million if all individuals screened in 2022 were covered by private insurance. The study attributes the savings to a reduction in follow-up diagnostic assessments, expensive follow-up procedures and procedure-related complications.
Health Technology Insights: Curve Dental Introduces AI-Assisted Notations Powered by Bola AI
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
